2-氯-5-正戊嘧啶 | 154466-62-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-5-正戊嘧啶
• 中文别名: 2-氯-5-戊基嘧啶；2-氯-5-正戊嘧啶,98%
• 英文名称: 2-chloro-5-pentylpyrimidine
• 英文别名: 2-chloro-5-n-pentylpyrimidine
• CAS: 154466-62-3
• 化学式: C₉H₁₃ClN₂
• mdl: MFCD04038093
• 分子量: 184.669
• InChiKey: WMARUIMXVALOMF-UHFFFAOYSA-N

物化性质

• 沸点：
  124°C/3mm
• 密度：
  1.085
• 闪点：
  124°C/3mm
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933599090

制备方法与用途

制备方法

医药生物化工中间体。

用途简介

（内容待补充）

反应信息

• 作为反应物：
  描述：

  2-氯-5-正戊嘧啶 在 copper(l) iodide 、 四(三苯基膦)钯 氢氧化钾 、 copper(l) iodide 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(5-pentylpyrimidin-2-yl)furo[2,3-d]pyrimidin-2-one
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of 6-(Alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one Nucleosides and Analogues with Ethynyl, Ethenyl, and Ethyl Spacers at C6 of the Furopyrimidine Core

  摘要：

  Sonogashira coupling strategies were employed to synthesize new furo[2,3-d]pyrimidin-2(3H)-one (FuPyrm) 2'-deoxynucleoside analogues. Partial or complete reduction of ethyne-linked compounds afforded ethenyl-and ethyl-linked derivatives. Levels of inhibition of varicella-zoster virus (VZV), human cytomegalovirus (HCMV), a broad range of other DNA and RNA viruses, and several cancer cell lines were evaluated in cell cultures. The anti-VZV potency decreased with increasing rigidity of the side chain at C6 of the FuPyrm ring in the order dec-1-yn-1-yl < dec-1-en-1-yl < decan-1-yl. In contrast, compounds with a rigid ethynyl spacer between C6 of the FuPyrm ring and a 4-alkylphenyl moiety were more potent inhibitors of VZV than the corresponding derivatives with an ethyl spacer. Replacement of the phenyl moiety in 6-(4-alkylphenyl) derivatives with a pyridine ring (in either regioisomeric orientation) gave analogues with increased solubility in methanol but reduced anti-VZV potency, and replacement with a pyrimidine ring reduced the anti-VZV activity even further. The pyridine-ring-containing analogues were similar to 20-fold more potent inhibitors of VZV than acyclovir but were similar to 6-fold less potent than BVDU and similar to 60-fold weaker than the most active 6-(4-pentylphenyl) -substituted prototype.

  DOI：

  10.1021/jm070210n
• 作为产物：
  描述：

  2-amino-5-(pent-1-yn-1-yl)pyrimidine 在 palladium on activated charcoal 三甲基氯硅烷 、 亚硝酸苄基三乙基铵 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 24.0h， 生成 2-氯-5-正戊嘧啶
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of 6-(Alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one Nucleosides and Analogues with Ethynyl, Ethenyl, and Ethyl Spacers at C6 of the Furopyrimidine Core

  摘要：

  Sonogashira coupling strategies were employed to synthesize new furo[2,3-d]pyrimidin-2(3H)-one (FuPyrm) 2'-deoxynucleoside analogues. Partial or complete reduction of ethyne-linked compounds afforded ethenyl-and ethyl-linked derivatives. Levels of inhibition of varicella-zoster virus (VZV), human cytomegalovirus (HCMV), a broad range of other DNA and RNA viruses, and several cancer cell lines were evaluated in cell cultures. The anti-VZV potency decreased with increasing rigidity of the side chain at C6 of the FuPyrm ring in the order dec-1-yn-1-yl < dec-1-en-1-yl < decan-1-yl. In contrast, compounds with a rigid ethynyl spacer between C6 of the FuPyrm ring and a 4-alkylphenyl moiety were more potent inhibitors of VZV than the corresponding derivatives with an ethyl spacer. Replacement of the phenyl moiety in 6-(4-alkylphenyl) derivatives with a pyridine ring (in either regioisomeric orientation) gave analogues with increased solubility in methanol but reduced anti-VZV potency, and replacement with a pyrimidine ring reduced the anti-VZV activity even further. The pyridine-ring-containing analogues were similar to 20-fold more potent inhibitors of VZV than acyclovir but were similar to 6-fold less potent than BVDU and similar to 60-fold weaker than the most active 6-(4-pentylphenyl) -substituted prototype.

  DOI：

  10.1021/jm070210n

文献信息

• Substituted Pyridine Compound
  申请人：Nakamura Tsuyoshi

  公开号：US20130109653A1

  公开（公告）日：2013-05-02

  The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R 1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

  本发明提供了一种取代吡啶化合物或其药理学上可接受的盐，具有优异的CETP抑制活性，并可用作药物。本发明提供了一种由通式（I）表示的化合物，其中R1为H，可选地取代的烷基，OH，可选地取代的烷氧基，烷基磺酰基，可选地取代的氨基，羧基，可选地取代的羰基，CN，卤素，可选地取代的苯基，可选地取代的芳香杂环基，可选地取代的饱和杂环基，可选地取代的饱和杂环氧基或可选地取代的饱和杂环羰基等。
• [EN] AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF<br/>[FR] AGONISTES ET ANTAGONISTES DU RÉCEPTEUR S1P5, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBOTT LAB

  公开号：WO2010093704A1

  公开（公告）日：2010-08-19

  Disclosed are compounds that are agonists or antagonists of the S1P5 receptor, compositions comprising said compounds, and methods of using said compounds and compositions. In certain embodiments, said compounds are 1-benzylazetidine-3-carboxylic acid derivatives. In certain embodiments, said methods relate to the treatment of neuropatic pain and/or a neurodegenerative disorder. In certain embodiments, said compounds may be used in combination with a second therapeutic agent.

  本文披露了作为S1P5受体激动剂或拮抗剂的化合物，包括含有这些化合物的组合物，以及使用这些化合物和组合物的方法。在某些实施例中，这些化合物是1-苄基氮杂环丙氨酸衍生物。在某些实施例中，这些方法涉及治疗神经痛和/或神经退行性疾病。在某些实施例中，这些化合物可以与第二治疗剂结合使用。
• Pyrimidine derivative, liquid crystal composition comprising the derivative, and liquid crystal display device fabricated by using the composition
  申请人：Chisso Corporation

  公开号：US06326065B1

  公开（公告）日：2001-12-04

  Liquid crystalline compounds having a comparatively high voltage holding ratio, high &Dgr;n and high &Dgr;&egr;, and excellent miscibility with known liquid crystalline compounds at low temperatures. The novel compounds have the formula (1) wherein R represents hydrogen atom or an alkyl group having 1 to 20 carbon atoms; n1 and n2 are independently 0, 1, or 2 provided that the sum of n1 and n2 is 1 or 2; ring A and ring B independently represent 1,4-phenylene, fluorine substituted 1,4-phenylene expressed by the formula (a) in the specification or 1,4-cyclohexylene provided that at least one of ring A and ring B is fluorine substituted 1,4-phenylene expressed by the formula (a); Za, Zb, and Zc independently represent single bond, —CH2CH2—, —COO—, —CF2O—, or —CH2CH2CH2CH2—; Q1, Q2, Q3, Q4, Q5, Q6, and Q7 independently represent hydrogen atom, a halogen atom, or methyl group provided that when at least one of Za, Zb, and Zc is —CH2CH2—, then Q2 is fluorine atom, and that when Za, Zb, and Zc are all single bonds, then Q1, Q2, Q3, Q4, Q5, Q6, and Q7 independently represent hydrogen atom or fluorine atom; Y represents hydrogen atom, a halogen atom, or a halogenated alkyl group having 1 to 5 carbon atoms; and each atom constituting this compound may be replaced by its isotope.

  具有相对较高的电压保持比、高Δn和高Δε值，并且在低温下与已知液晶化合物具有良好的溶解性的液晶化合物。这些新颖的化合物具有以下结构式（1）其中R代表氢原子或具有1至20个碳原子的烷基基团；n1和n2独立地为0、1或2，前提是n1和n2的和为1或2；环A和环B独立地代表1,4-苯基、规定中的公式（a）表示的氟取代1,4-苯基或1,4-环己基，前提是环A和环B中至少有一个是由公式（a）表示的氟取代1,4-苯基；Za、Zb和Zc独立地代表单键、—CH2CH2—、—COO—、—CF2O—或—CH2CH2CH2CH2—；Q1、Q2、Q3、Q4、Q5、Q6和Q7独立地代表氢原子、卤素原子或甲基基团，前提是当至少其中一个为—CH2CH2—时，Q2为氟原子，以及当Za、Zb和Zc均为单键时，Q1、Q2、Q3、Q4、Q5、Q6和Q7独立地代表氢原子或氟原子；Y代表氢原子、卤素原子或具有1至5个碳原子的卤代烷基基团；此化合物的每个原子都可以被其同位素取代。
• Chlorobenzene derivatives, liquid-crystal composition, and liquid-crystal display elements
  申请人：Chisso Corporation

  公开号：US06329027B1

  公开（公告）日：2001-12-11

  Provided are liquid crystalline compounds having excellent physical properties and being excellent in miscibility with other liquid crystal materials; liquid crystal compositions comprising the crystalline compound; and liquid crystal display device fabricated by using the liquid crystal composition; the liquid crystalline compounds being specific chlorobenzene derivatives expressed by the general formula (1) Ra—A1—Z1—A2&Parenopenst;Z2—A3&Parenclosest;m&Parenopenst;Z3—A4&Parenclosest;nRb  (1) wherein Ra, Rb, A1 to A4, Z1 to Z3, m, and n are herein defined.

  提供了具有优异物理性能并且与其他液晶材料混溶性优秀的液晶化合物；包括该晶体化合物的液晶组合物；以及使用该液晶组合物制造的液晶显示装置。该液晶化合物是由一般式（1）表示的特定氯苯衍生物，其为液晶化合物。其中，Ra，Rb，A1到A4，Z1到Z3，m和n在文中有定义。
• Cyanophenylpyri (MI)dine derivatives and liquid-crystalline medium
  申请人：Merck Patent Gesellschaft mit beschrankter Haftung

  公开号：US05454975A1

  公开（公告）日：1995-10-03

  Cyanopyrimidine derivatives of formula I ##STR1## in which R.sup.1 is an unsubstituted or at least mono-halogen-substituted alkyl or alkoxy radical having 1 to 15 carbon atoms, where one or more CH.sub.2 groups in these radicals may also, in each case independently of one another, be replaced by --CH.dbd.CH--, --O--, --S--, ##STR2## --CO--, --CO--O--, --O--CO-- or --O--CO--O-- in such a way that oxygen atoms are not linked directly to one another, X.sup.1, Y.sup.1 and Z.sup.1 are each, independently of one another, N or CF, X.sup.2, Y.sup.2 and Z.sup.2 are each, independently of one another, N, CF or CH, and n is 0, 1 or 2, with the proviso that at least one of the groups X.sup.1, Y.sup.1 and Z.sup.1 is N, can be used as components of liquid-crystalline media for electro-optical displays.

  公式I中的氰基嘧啶衍生物 ##STR1## 其中R.sup.1是未取代或至少单卤素取代的1-15个碳原子的烷基或烷氧基，其中这些基中的一个或多个CH.sub.2基团也可以独立地被--CH.dbd.CH--，--O--，--S--，##STR2## --CO--，--CO--O--，--O--CO--或--O--CO--O--替换，使得氧原子不直接连接在一起，X.sup.1，Y.sup.1和Z.sup.1分别独立地为N或CF，X.sup.2，Y.sup.2和Z.sup.2分别独立地为N，CF或CH，n为0，1或2，但至少X.sup.1，Y.sup.1和Z.sup.1中的一个为N，可以用作电光显示的液晶介质组分。